GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dicerna Pharmaceuticals Inc (NAS:DRNA) » Definitions » EBITDA per Share

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) EBITDA per Share : $-1.55 (TTM As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Dicerna Pharmaceuticals EBITDA per Share?

Dicerna Pharmaceuticals's EBITDA per Share for the three months ended in Sep. 2021 was $-0.19. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2021 was $-1.55.

During the past 3 years, the average EBITDA per Share Growth Rate was 18.10% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 14.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Dicerna Pharmaceuticals's EBITDA per Share or its related term are showing as below:

DRNA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -40.9   Med: 2.4   Max: 19.9
Current: 18.1

During the past 10 years, the highest 3-Year average EBITDA per Share Growth Rate of Dicerna Pharmaceuticals was 19.90% per year. The lowest was -40.90% per year. And the median was 2.40% per year.

DRNA's 3-Year EBITDA Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 6.1 vs DRNA: 18.10

Dicerna Pharmaceuticals's EBITDA for the three months ended in Sep. 2021 was $-14.8 Mil.

During the past 3 years, the average EBITDA Growth Rate was -23.00% per year. During the past 5 years, the average EBITDA Growth Rate was -16.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 10 years, the highest 3-Year average EBITDA Growth Rate of Dicerna Pharmaceuticals was -8.20% per year. The lowest was -98.20% per year. And the median was -26.70% per year.


Dicerna Pharmaceuticals EBITDA per Share Historical Data

The historical data trend for Dicerna Pharmaceuticals's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dicerna Pharmaceuticals EBITDA per Share Chart

Dicerna Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.83 -2.71 -1.57 -1.74 -1.49

Dicerna Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.48 -0.38 -0.50 -0.19

Dicerna Pharmaceuticals EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Dicerna Pharmaceuticals's EBITDA per Share for the fiscal year that ended in Dec. 2020 is calculated as

EBITDA per Share(A: Dec. 2020 )
=EBITDA/Shares Outstanding (Diluted Average)
=-110.51/74.187
=-1.49

Dicerna Pharmaceuticals's EBITDA per Share for the quarter that ended in Sep. 2021 is calculated as

EBITDA per Share(Q: Sep. 2021 )
=EBITDA/Shares Outstanding (Diluted Average)
=-14.807/77.747
=-0.19

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dicerna Pharmaceuticals  (NAS:DRNA) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Dicerna Pharmaceuticals EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Dicerna Pharmaceuticals's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
75 Hayden Avenue, Lexington, MA, USA, 02421
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, cardiovascular diseases, cancers, and other liver problems. The company uses its ribonucleic acid interference technology platform to develop its products. In addition, Dicerna's proprietary GalXC technology focuses on silencing disease-causing genes. The product candidates are nedosiran (for primary hyperoxaluria), belcesiran (for genetic liver disease), DCR-PCSK9 (for cardiovascular disease), and RG6346 (for hepatitis B virus) among others. Dicerna generates revenue by forming collaborative relationships with pharmaceutical companies such as Eli Lilly, Roche, Novo Nordisk, and others.
Executives
Bob D Brown officer: See Remarks 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Shreeram Aradhye officer: EVP & Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Marc D Kozin director
Douglas Fambrough director, officer: President and CEO C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
James B Weissman officer: Chief Operating Officer & EVP C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Regina M. Paglia officer: Chief Human Resources Officer C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Robert D. Ciappenelli officer: Chief Commercial Officer DICERNA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Stephen K Doberstein director 129 ELSIE STREET, SAN FRANCISCO CA 94110
Patrick M. Gray director C/O CIVITAS SOLUTIONS, INC. 313 CONGRESS STREET, 6TH FLOOR BOSTON MA 02210
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Martin I Freed director 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Stephen J Hoffman director C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Headlines

From GuruFocus

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Business Wire Business Wire 10-01-2021

Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021

By Business Wire Business Wire 11-02-2021